Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Metagenomi to Regain Full Development Rights to its Wholly-owned Base Editing and RIGS Systems
Details : Metagenomi and Moderna have mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1), and rights to develop the PH1 program, as well as all other rights granted under the col...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : J.P. Morgan
Deal Size : $93.7 million
Deal Type : Public Offering
Metagenomi Announces Closing of Initial Public Offering
Details : The net proceeds will be used for continued research and development of next-generation gene editing technology to develop company's therapeutic portfolio, including metabolic disease, hemophilia A, cardi...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 13, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : J.P. Morgan
Deal Size : $93.7 million
Deal Type : Public Offering
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : J.P. Morgan
Deal Size : $93.7 million
Deal Type : Public Offering
Metagenomi Announces Pricing of Initial Public Offering
Details : The net proceeds will be used for continued research and development of next-generation gene editing technology to develop company's therapeutic portfolio, including metabolic disease, hemophilia A, cardi...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 08, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : J.P. Morgan
Deal Size : $93.7 million
Deal Type : Public Offering
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : J.P. Morgan
Deal Size : $86.9 million
Deal Type : Public Offering
Gene Editing Biotech Metagenomi Plans Modest $87M IPO
Details : The net proceeds will be used for continued research and development of next-generation gene editing technology to develop company's therapeutic portfolio, including metabolic disease, hemophilia A, cardi...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : J.P. Morgan
Deal Size : $86.9 million
Deal Type : Public Offering
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Novo Holdings
Deal Size : $275.0 million
Deal Type : Series B Financing
Details : Company plans to nominate additional therapeutic targets to its proprietary genetic medicines pipeline, fueled by its automated discovery engine and versatile gen...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Novo Holdings
Deal Size : $275.0 million
Deal Type : Series B Financing
Lead Product(s) : RNA-based Therapy
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Ionis Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Ionis Partners with Metagenomi to Add Gene Editing to Its Broad Technology Platform
Details : CRISPR gene editing is a technology that modifies the sequence of DNA in cells utilizing a specific RNA-guided nuclease (Cas enzyme). Gene editing enzymes act as molecular word processors to correct the g...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $80.0 million
November 14, 2022
Lead Product(s) : RNA-based Therapy
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Ionis Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AFNT-111
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Affini-T Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership will leverage Metagenomi’s proprietary gene editing systems to complement Affini-T’s state-of-the-art TCR discovery and synthetic biology platforms to generate groundbreaking cell ther...
Brand Name : AFNT-111
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 15, 2022
Lead Product(s) : AFNT-111
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Affini-T Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : TCR-cell Therapy
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CRISPR-associated gene-editing systems (Immuno-Oncology (TCR)- Solid tumor) discovered in metagenomic samples enable efficient genome engineering in multiple primary immune cell types.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 05, 2022
Lead Product(s) : TCR-cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : In-vivo Gene Editing Therapeutics
Therapeutic Area : Genetic Disease
Study Phase : Discovery Platform
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies to accelerate the development of in vivo gene edi...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 02, 2021
Lead Product(s) : In-vivo Gene Editing Therapeutics
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery Platform
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?